Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Mpox has caused two international public health emergencies; no therapies have established efficacy. ACTG A5418/STOMP is a phase 3 randomized placebo-controlled double-blind trial evaluating the efficacy of tecovirimat, an antiviral with animal data supporting its use for orthopox infections. Methods Participants ≥18 years with symptomatic laboratory-confirmed or presumptive mpox <14 days were randomized 2:1…
Background A5379 primary analysis demonstrated that 2- and 3-dose HepB-CpG (2-CpG, 3-CpG) achieved superior seroprotective response (SPR defined as anti-HBs ≥10 mIU/mL) compared to 3-dose HepB-alum (3-alum) in PWH with prior HBV vaccine non-response (Group A), and 100% SPR was achieved with 3-CpG in vaccine-naïve PWH (Group B). SPR durability is now evaluated. Methods A5379…
Background People with HIV (PWH) and CMV face an increased risk of frailty and aging-related outcomes, yet the causal role of CMV remains untested. Methods A randomized trial assessed whether 48 weeks of letermovir, a CMV terminase inhibitor, reduced plasma sTNFR2 levels (primary endpoint) and other immunologic and functional aging-related outcomes in PWH seropositive for…
Background The World Health Organization endorses 3 months of weekly isoniazid and rifapentine (3HP) as TB preventive therapy (TPT) in people with HIV (PWH) on once-daily dolutegravir (DTG)-based antiretroviral treatment (ART). Optimal dosing of DTG to maintain HIV viral suppression in pregnancy while taking 3HP or 1 month of daily isoniazid and rifapentine (1HP) has…
Background Financial incentives are known to help initiate routine healthcare behaviors. However, a more nuanced understanding of behavioral responses to incentives over time, particularly after they are removed, could guide more effective interventions. In our study, we explore the dynamic effectiveness of small, short-term monthly financial incentives on HIV care-seeking behaviors during and after incentive…
Background Non-adherence to oral TDF/FTC PrEP reduces efficacy for HIV prevention, including in pregnant and postpartum women (PPW). Urine tenofovir (TFV) testing detects dosing in past 72 hours in people taking oral PrEP, but there are few insights into whether providing PPW with feedback on urine TFV test results can support PrEP adherence. We examined…
Background Clinic-based hypertension screening and treatment for people with and without HIV depends on consistent clinic engagement. Retention is challenging in rural areas, especially for people with severe hypertension which typically requires more frequent visits than stable HIV. We hypothesized that Ministry of Health (MoH) community health workers (CHWs) could be leveraged to improve hypertension…
Background In the CHAPAS-4 trial of second-line antiretroviral therapy following NNRTI-based first-line, 96-week efficacy was superior for tenofovir alafenamide (TAF) vs standard-of-care (SOC: abacavir (ABC)/zidovudine (ZDV)), and for dolutegravir (DTG) vs ritonavir-boosted lopinavir (LPV/r)/atazanavir (ATV/r). We present data on emergent resistance and associations between baseline resistance and virological failure at week 96 (W96). Methods Randomisation…
Background HIV-1 replication is associated with the generation of various nucleic acid products that may act as ligands for cytosolic innate immune sensors including RIG-like receptors (RLRs). However, to induce an effective innate immune response, RLRs need to be primed by actin disturbances, sensed by R12C (Acharya et al., Cell 2022). While mounting evidence suggests…
Background Mpox, a zoonotic disease caused by the Monkeypox virus (MPXV) within the Orthopoxvirus family, includes two major clades: Clade I, associated with severe disease and higher mortality, and Clade II. On August 14, 2024, the World Health Organization (WHO) declared Mpox a public health emergency of international concern following multi-country outbreaks since May 2022.…